Grifols Receives Conditional Health Canada Approval to Begin Paid Plasma Collection at New Winnipeg Facility

Grifols secures conditional license for Winnipeg's first paid plasma center. Operation starts late spring under strict Health Canada safety oversight.

By: AXL Media

Published: Apr 4, 2026, 7:59 AM EDT

Source: Information for this report was sourced from CBC News

Health Canada Issues Performance Based Authorization

The federal health regulator has granted a conditional operating license to Grifols, a Barcelona-based multinational specializing in plasma-derived medicines. This authorization allows the company to move forward with its long-anticipated donation center located in south Winnipeg, provided it meets specific safety and quality benchmarks during its initial phase. According to Health Canada, the conditional nature of the permit ensures that the facility adheres to the strict standards set out in the Food and Drugs Act while transitioning from a construction phase to a fully functional medical collection site.

The Economic Model of Paid Plasma Donation

Unlike the traditional voluntary model managed by Canadian Blood Services, the Grifols facility will utilize a private-payment system to attract donors. Under this structure, individuals who provide plasma will receive monetary compensation for their time and contribution, a practice that has sparked debate across various Canadian jurisdictions. According to company representatives, this model is essential for securing the high volumes of plasma required to manufacture specialized treatments for rare and chronic diseases. The Winnipeg site represents the first of several planned centers intended to bolster the domestic supply of plasma-derived medicinal products.

Operational Timelines and Facility Readiness

With the conditional license secured, Grifols is now entering the final stages of equipment calibration and staff training at the Winnipeg location. The company anticipates that the doors will officially open to the public by the end of May or early June, depending on the completion of final regulatory inspections. According to project lead statements, the facility has been outfitted with high-capacity aphidesis machines designed to separate plasma from whole blood and return the remaining components to the donor. This technical readiness is the culmination of nearly two years of infrastructure development within the Manitoba capital.